Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS
Paula Rodríguez‐Otero, Peter M. Voorhees, Mario Boccadoro, Jacob P. Laubach, Hermann Einsele, Douglas W. Sborov, Meletios A Dimopoulos, Annemiek Broijl, Roberto Mina, Andrew Spencer, Fredrik Schjesvold, Rebecca Silbermann, Francesca Gay, Luciano J. Costa, Aurore Perrot, Yanfang Liu, Jianping Wang, Anna Sitthi-Amorn, Robin Carson, Annelore Cortoos, Saad Z. Usmani, Paul G. Richardson, Philippe Moreau, Pieter Sonneveld, Jonathan L. Kaufman (2025). Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS. , 25(10), DOI: https://doi.org/10.1016/j.clml.2025.04.007.
Article24 days agoSequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
Niels W.C.J. van de Donk, Philippe Moreau, Jesús F. San Miguel, María‐Victoria Mateos, Meletios A Dimopoulos, Sonja Zweegman, Francesca Gay, Monika Engelhardt, Roberto Mina, Elena Zamagni, Michel Delforge, Meral Beksaç, Andrew Spencer, Fredrik Schjesvold, Christoph Driessen, Martin Kaiser, Aurore Perrot, Ralph Wäsch, Charlotte L.B.M. Korst, Annemiek Broijl, Cyrille Touzeau, Salomon Manier, Roman Hájek, Jelena Bila, Güldane Cengiz Seval, Michael O’Dwyer, Heinz Ludwig, Carlos Fernández de Larrea, Rakesh Popat, Pellegrino Musto, Paula Rodríguez‐Otero, Kwee Yong, K. Martin Kortüm, Leo Rasche, Evangelos Terpos, Marc S. Raab, Mario Boccadoro, Pieter Sonneveld, Hermann Einsele (2025). Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network. , 9(11), DOI: https://doi.org/10.1002/hem3.70260.
Article24 days agoTeclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Luciano J. Costa, Nizar J. Bahlis, Aurore Perrot, Ajay K. Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gastón Caeiro, Alain Kentos, Vânia Hungria, Donna Reece, Ting Niu, Anne K. Mylin, Charlotte T. Hansen, Raphael Teipel, Britta Besemer, Meletios A Dimopoulos, Elena Zamagni, Satoshi Yoshihara, Kihyun Kım, Chang Ki Min, Paul A. F. Geerts, Elena van Leeuwen-Segarceanu, Agata Tyczyńska, Juan Luis Reguera, Magnus Johansson, Markus Hansson, Mehmet Turgut, Mark Grey, Surbhi Sidana, Paula Rodríguez‐Otero, Joaquín Martínez‐López, Hamza Hashmi, Robin Carson, Rachel Kobos, Weili Sun, Kristen Lantz, Anne Seifert, Deborah Briseno-Toomey, Lisa O’Rourke, Ingrid Maria Cecilia Rubin, Diego Vieyra, Lijuan Kang, María‐Victoria Mateos (2025). Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. , 394(8), DOI: https://doi.org/10.1056/nejmoa2514663.
Article24 days agoPhase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3
María-Victoria Mateos, Nizar J. Bahlis, Aurore Perrot, Ajay K. Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gastón Caeiro, Alain Kentos, Vânia Hungria, Donna Reece, Ting Niu, Anne K. Mylin, Charlotte T. Hansen, Raphael Teipel, Britta Besemer, Meletios A Dimopoulos, Elena Zamagni, Satoshi Yoshihara, Kihyun Kım, Chang‐Ki Min, Paulus A.F. Geerts, Elena van Leeuwen-Segarceanu, Agata Tyczyńska, Juan Luis Reguera, Magnus Johansson, Markus Hansson, Mehmet Turgut, Mark Grey, Surbhi Sidana, Paula Rodríguez‐Otero, Joaquín Martínez‐López, Hamza Hashmi, Richard G. Carson, Rachel Kobos, Weili Sun, Kristen Lantz, Anne Seifert, Debbie Briseno-Toomey, Lisa O’Rourke, Ingrid Maria Cecilia Rubin, Diego Vieyra, Lijuan Kang, Luciano J. Costa (2025). Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3. , 146(Supplement 2), DOI: https://doi.org/10.1182/blood-2025-lba-6.
Article24 days agoHigh Accuracy of Next-Generation Flow (NGF) in Predicting Measurable Residual Disease by Next-Generation Sequencing (NGS) in the 10−6 Range: A Prospective Comparison Within the Phase III IsKia Trial
Mattia D’Agostino, Mark van Duin, Wilfried Roeloffzen, Meletios A Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Roberto Mina, Albert Oriol, Eirini Katodritou, Ka Lung Wu, Paula Rodríguez‐Otero, Roman Hájek, Daniela Oddolo, Esther de Waal, Enrique M. Ocio, Mark-David Levin, María-Victoria Mateos, Paula F. Ypma, Fredrik Schjesvold, Joan Bladé, Hermann Einsele, Mario Boccadoro, Pieter Sonneveld, Annemiek Broijl, Francesca Gay (2025). High Accuracy of Next-Generation Flow (NGF) in Predicting Measurable Residual Disease by Next-Generation Sequencing (NGS) in the 10−6 Range: A Prospective Comparison Within the Phase III IsKia Trial. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)03429-9.
Article24 days ago